Old drugs, new uses

Pediatric Dentistry

Volumn 33, Issue 1, 2011, Pages 67-74

  Da Fonseca, Marcio A ^a   Casamassimo, Paul ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Children with special health care needs; Hospital dentistry; Pediatric dentistry; Pharmacology

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; BOTULINUM TOXIN A; HYDROXYUREA; IMMUNOGLOBULIN; METHOTREXATE; THALIDOMIDE;

ADOLESCENT; CHILD; DENTISTRY; DRUG REPOSITIONING; HUMAN; OFF LABEL DRUG USE; REVIEW;

ADOLESCENT; ANTICONVULSANTS; ASPIRIN; BOTULINUM TOXINS, TYPE A; CHILD; DIPHOSPHONATES; DRUG REPOSITIONING; HUMANS; HYDROXYUREA; IMMUNOGLOBULINS, INTRAVENOUS; METHOTREXATE; OFF-LABEL USE; PEDIATRIC DENTISTRY; THALIDOMIDE;

EID: 79953783213     PISSN: 01641263     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Landmark CJ. Antiepileptic drugs in nonepilepsy disorders. Relations between mechanisms of action and clinical efficacy. CNS Drugs 2008;22:27-47.
2. Ettinger AB, Argoff CE. Use of antiepileptic drugs for nonepileptic conditions: Psychiatric disorders and chronic pain. Neurotherapeutics 2007;4:75-83. (Pubitemid 46110806)
3. Kelleher KJ, McInerny T, Gradner WP, Childs GE, Wasserman RC. Increasing identification of psychosocial problems: 1979-1996. Pediatrics 2000;105:1313-21. (Pubitemid 30346903)
4. McElroy SL, Guerdjikova AI, Martens B, Keck PE Jr, Pope HG, Hudson JI. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs 2009;23: 139-56.
5. Cordas TA, Tavares H, Calderoni DM, Stump GV, Ribeiro RB. Oxcarbazepine for self-mutilating bulimic patients. Int J Neuropsychopharmacol 2006;9:769-71. (Pubitemid 46122776)
6. Michaelis M, Doerr HW, Cinatl J Jr. Valproic acid as anti-cancer drug. Curr Pharmacol Design 2007;13: 3378-93. (Pubitemid 350201672)
7. Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: New uses for an old product. Drug Discov Today 2005;10:107-14. (Pubitemid 40247808)
8. Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol 2007;39:1489-99. (Pubitemid 47031027)
9. Rosenbach M, Werth VP. Dermatologic therapeutics: Thalidomide. A practical guide. Dermatol Ther 2007;20: 175-86.
10. Kari JA, Shah V, Dillon MJ. Behçet's disease in UK children: Clinical features and treatment including thalidomide. Rheumatol 2001;40:933-8.
11. Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: Properties, mode of action, and practical use in dermatology. Acta Derm Venereol 2007;87:206-18. (Pubitemid 47226887)
12. Udi N, Yehuda S. Intravenous immunoglobulin: Indications and mechanisms in cardiovascular diseases. Autoimmun Rev 2008;7:445-52.
13. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: The Massachusetts General Hospital data and a review of the literature. Transfusion 2006;46:741-53.
14. Looney RJ, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Pract Res Clin Haematol 2006;19:3-25. (Pubitemid 43118860)
15. Leong H, Stachnik J, Bonk ME, Matuszewski KA. Unlabeled uses of intravenous immune globulin. Am J Health-Syst Pharm 2008;65:1815-24.
16. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: Hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008;148:932-8. (Pubitemid 351860825)
17. De Benedittis M, Petruzzi M, Giardina C, Lo Muzio L, Favia G, Serpico R. Oral squamous cell carcinoma during long-term treatment with hydroxyurea. Clin Exp Dermatol 2004;29:605-7. (Pubitemid 39573645)
18. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: A systematic review for efficacy and toxicity in children. Pediatrics 2008;122:1332-42.
19. Khatib R, Rabah R, Sarnaik SA. The spleen in the sickling disorders: An update. Pediatr Radiol 2009;39:17-22.
20. da Fonseca MA, Oueis HS, Casamassimo P. Sickle cell anemia: A review for the pediatric dentist. Pediatr Dent 2007;29:159-69.
21. Said S, Jeffes EWB, Weinstein GD. Methotrexate. Clin Dermatol 1997;15:781-97. (Pubitemid 27411309)
22. Niehues T, Lankisch P. Recommendations for the use of methotrexate in juvenile idiopathic arthritis. Paediatr Drugs 2006;8:347-56. (Pubitemid 44912719)
23. Federal Drug Administration. Available at: www.access data.fda.gov/drugsatfda-docs/label/2004/1171951r106-methotrexate-lbl.pdf. Accessed July 21, 2009.
24. Kalantzis A, Marshman Z, Falconer DT, Morgan PR, Odell EW. Oral effects of low-dose methotrexate treatment. Oral Surg Oral Med Oral Pathol Radiol Endod 2005;100:52-62. (Pubitemid 40813391)
25. de Maio M. Therapeutic uses of botulinum toxin: From facial palsy to autonomic disorders. Expert Opin Biol Ther 2008;8:791-8. (Pubitemid 351860208)
26. Erbguth FJ. From poison to remedy: The chequered history of botulinum toxin. J Neural Transm 2008;115: 559-65. (Pubitemid 351534031)
27. Federal Drug Administration. Available at: www.access data.fda.gov/drugstafda-docs/label/2004/103000s5050lbl.pdf. Accessed July 24, 2009.
28. Nolan KW, Cole LL, Liptak GS. Use of botulinum toxin type A in children with cerebral palsy. Phys Ther 2006;86:573-84.
29. DasGupta R, Murphy FL. Botulinum toxin in paediatric urology: A systematic literature review. Pediatr Surg Int 2009;25:19-23.
30. Capaccio P, Torretta S, Osio M, et al. Botulinum toxin therapy: A tempting tool in the management of salivary secretory disorders. Am J Otolaryngol 2008;29:333-8.
31. Pena AH, Cahill AM, Gonzalez L, Baskin KM, Kim H, Towbin RB. Botulinum toxin A injection of salivary glands in children with drooling and chronic aspiration. J Vasc Interv Radiol 2009;20:368-73.
32. Schwartz M, Freund B. Treatment of temporomandibular disorders with botulinum toxin. Clin J Pain 2002; 18:S198-S203. (Pubitemid 35285605)
33. Bianchi ML. How to manage osteoporosis in children. Best Pract Res Clin Rheumatol 2005;19:991-1005. (Pubitemid 41748510)
34. Landesberg R, Eisig S, Fennoy I, Siris E. Alternative indications for bisphosphonate therapy. J Oral Maxillofac Surg 2009;67(suppl 1):27-34.
35. Castillo H, Samson-Fang L. Effects of bisphosphonates in children with osteogenesis imperfecta: An AACPDM systematic review. Develop Med Child Neurol 2008;51: 17-29.
36. Bachrach LK, Ward LM. Clinical review: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009;94:400-9.
37. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on a bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 2009;67(suppl 1):2-12.
38. Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of placing dental implants in patients taking oral bisphosphonates: A review of 115 cases. J Oral Maxillofac Surg 2009;66:223-30.
39. Zahrowski JJ. Bisphosphonate treatment: An orthodontic concern calling for a proactive approach. Am J Orthop Dentofacial Orthop 2007;131:311-20.
40. Kamoun-Goldrat A, Ginisty D, Le Merrer M. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci 2008;116:195-8.
41. Gonzalez-Moles MA, Bagan-Sebastian JV. Alendronaterelated oral mucosa ulcerations. J Oral Pathol Med 2000; 29:514-8.
42. Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008;34:58-73. (Pubitemid 351640882)
43. Israels SJ, Michelson AD. Antiplatelet therapy in children. Thromb Res 2006;118:75-83.
44. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs. American College of Chest Physicians evidencebased clinical practice guidelines. 8th ed. Chest 2008; 133:199S-233S. (Pubitemid 351894914)
45. Michael JB, Sztajnkrycer MD. Deadly pediatric poisons: Nine common agents that kill at low doses. Emerg Clin N Am 2004;22:1019-50. (Pubitemid 39341170)
46. Schör K. Aspirin and Reye syndrome: A review of the evidence. Paediatr Drugs 2007;9:195-204.
47. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy. American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008;133:299S-339S. (Pubitemid 351894915)
48. Monagle P, Chalmers E, Chan A, et al. American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008;133:887S-968S.